Compare · DERM vs OGN

DERM vs OGN

Side-by-side comparison of Journey Medical Corporation (DERM) and Organon & Co. (OGN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DERM and OGN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • OGN is the larger of the two at $3.65B, about 29.5x DERM ($123.9M).
  • OGN has been more active in the news (11 items in the past 4 weeks vs 4 for DERM).
  • OGN has more recent analyst coverage (19 ratings vs 7 for DERM).
MetricDERMOGN
Company
Journey Medical Corporation
Organon & Co.
Price
-
-
Market cap
$123.9M
$3.65B
1M return
-
+1.16%
1Y return
-
+82.18%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2021
2021
News (4w)
4
11
Recent ratings
7
19
DERM

Journey Medical Corporation

Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

OGN

Organon & Co.

Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.

Latest DERM

Latest OGN